These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10845411)

  • 1. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins.
    Tice AD
    Drugs; 2000; 59 Suppl 3():29-35; discussion 47-9. PubMed ID: 10845411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages.
    Esposito S
    Drugs; 2000; 59 Suppl 3():19-28; discussion 47-9. PubMed ID: 10845410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Place of parenteral cephalosporins in the ambulatory setting: clinical evidence.
    Nathwani D
    Drugs; 2000; 59 Suppl 3():37-46; discussion 47-9. PubMed ID: 10845412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective.
    Wai AO; Frighetto L; Marra CA; Chan E; Jewesson PJ
    Pharmacoeconomics; 2000 Nov; 18(5):451-7. PubMed ID: 11151398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of parenteral cephalosporins for outpatients treatment of infections].
    Esposito S; Mazzei T; Novelli A
    Infez Med; 2001 Dec; 9(4):193-211. PubMed ID: 12087207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambulatory use of parenteral antibacterials: contemporary perspectives.
    Leggett JE
    Drugs; 2000; 59 Suppl 3():1-8; discussion 47-9. PubMed ID: 10845408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefotaxime and ceftriaxone use evaluation in pediatrics. Considerations of cost effectiveness.
    Lee CK; Glenn DJ
    Diagn Microbiol Infect Dis; 1995; 22(1-2):231-3. PubMed ID: 7587045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and Pharmacoeconomic Analysis of a Home Intravenous Antibiotic Infusion Program in Veterans.
    Ruh CA; Parameswaran GI; Wojciechowski AL; Mergenhagen KA
    Clin Ther; 2015 Nov; 37(11):2527-35. PubMed ID: 26471204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient parenteral antimicrobial therapy today.
    Paladino JA; Poretz D
    Clin Infect Dis; 2010 Sep; 51 Suppl 2():S198-208. PubMed ID: 20731577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective.
    Yong C; Fisher DA; Sklar GE; Li SC
    Int J Antimicrob Agents; 2009 Jan; 33(1):46-51. PubMed ID: 18823759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.
    Strehl E; Kees F
    Drugs; 2000; 59 Suppl 3():9-18; discussion 47-9. PubMed ID: 10845409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient parenteral antibiotic therapy in an academic practice in Rhode Island.
    Touzard Romo F; Resnick B; Perez-Cioe M; Flanigan TP; Kojic EM; Beckwith CG
    R I Med J (2013); 2014 Jan; 98(1):38-42. PubMed ID: 25562060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service.
    Durojaiye OC; Bell H; Andrews D; Ntziora F; Cartwright K
    Int J Antimicrob Agents; 2018 Jan; 51(1):26-32. PubMed ID: 28673610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use, appropriateness and outcomes of outpatient parenteral antimicrobial therapy.
    Hodgson KA; Huynh J; Ibrahim LF; Sacks B; Golshevsky D; Layley M; Spagnolo M; Raymundo CM; Bryant PA
    Arch Dis Child; 2016 Oct; 101(10):886-93. PubMed ID: 27166221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient parenteral antibiotic therapy in the elderly: an Italian observational multicenter study.
    Esposito S; Leone S; Noviello S; Ianniello F; Russo M; Foti G; Carpentieri MS; Cellesi C; Zanelli G; Cellini A; Girmenia C; De Lalla F; Maiello A; Maio P; Acone N; Marranconi F; Sabbatani S; Pantaleoni M; Ghinelli F; Soranzo ML; Viganò P; Re T; Viale P; Scudeller L;
    J Chemother; 2009 Apr; 21(2):193-8. PubMed ID: 19423473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of long half-life parenteral cephalosporins in ambulatory practice.
    Sauerwein M; Deamer RL; Prichard JG
    J Fam Pract; 1987 Jan; 24(1):47-51. PubMed ID: 3794613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambulatory antimicrobial use: the value of an outcomes registry.
    Nathwani D; Tice A
    J Antimicrob Chemother; 2002 Jan; 49(1):149-54. PubMed ID: 11751779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of cephalosporins for hospital formularies.
    Wilson WR
    Diagn Microbiol Infect Dis; 1995; 22(1-2):129-34. PubMed ID: 7587026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.